Composition for preventing or treating hyperoxia-induced lung injury comprising WKYMVm peptide as an active ingredient

Patent metadata

Field	Value
Publication number	US-10765720-B2
Application number	US-201816207441-A
Country	US
Kind code	B2
Filing date	Dec 3, 2018
Priority date	Dec 4, 2017
Publication date	Sep 8, 2020
Grant date	Sep 8, 2020

Abstract

A composition for alleviating, preventing, or treating hyperoxia-induced lung injury, the composition including the WKYMVm peptide as an active ingredient is described. The composition has an effect of increasing FPR2 activation and ERK phosphorylation, and also has an effect of improving alveolarization and angiogenesis in hyperoxia-induced lung injury models, and thus the composition is anticipated to be usefully used for the alleviation, prevention, or treatment of hyperoxia-induced lung injury, particularly bronchopulmonary dysplasia.

First claim

What is claimed is:

1. A method of treating hyperoxia-induced lung injury comprising:
administering to a subject in need thereof an effective amount of a WKYMVm peptide, the WKYMVm peptide comprising the sequence of SEQ ID NO: 1,
wherein the hypoxia-induced lung injury is bronchopulmonary dysplasia, and
wherein the effective amount of the WKYMVm is from 1-100 μM.

2. The method of claim 1 , wherein the WKYMVm peptide activates formyl-peptide receptor type 2 (FPR2).

3. The method of claim 1 , wherein the WKYMVm peptide increases the phosphorylation of an extracellular signal-regulated kinase (ERK).

4. The method of claim 1 , wherein the WKYMVm peptide induces angiogenesis.

5. The method of claim 1 , wherein the WKYMVm peptide reduces inflammation.

6. A method of alleviating hyperoxia-induced lung injury comprising:
administering to a subject in need thereof an effective amount of a WKYMVm peptide to an individual, the WKYMVm peptide comprising the sequence of SEQ ID NO: 1 ,
wherein the hypoxia-induced lung injury is bronchopulmonary dysplasia, and
wherein the effective amount of the WKYMVm is from 1-100 μM.

7. The method of claim 6 , wherein the WKYMVm peptide activates formyl-peptide receptor type 2 (FPR2).

8. The method of claim 6 , wherein the WKYMVm peptide increases the phosphorylation of an extracellular signal-regulated kinase (ERK).

9. The method of claim 6 , wherein the WKYMVm peptide induces angiogenesis.

10. The method of claim 6 , wherein the WKYMVm peptide reduces inflammation.

Assignees

• Samsung Life Public Welfare Foundation
• Nat Univ Pusan Ind Univ Coop Found

Inventors

• Chang Yun Sil
• Park Won Soon
• Ahn So Yoon
• Sung Dong Kyung
• Kim Young Eun
• Kim Jae Ho

Classifications

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K38/08 Primary

  Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A23V2200/314

  having an effect on lung or respiratory system · CPC title

• A23L33/18

  Peptides; Protein hydrolysates · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title